Jörg Ruof

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi request reprint Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required?
    Jörg Ruof
    Hannover Medical School, Hannover, Germany
    Arthritis Rheum 51:774-81. 2004
  2. pmc Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
    Jörg Ruof
    Roche Pharma AG, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Germany
    Drugs R D 15:221-6. 2015
  3. doi request reprint Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany
    Jörg Ruof
    Roche Pharma AG, Grenzach Wyhlen, Germany Medical School of Hanover, Hanover, Germany Electronic address
    Health Policy 118:242-54. 2014
  4. pmc Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
    Jörg Ruof
    Roche Pharma AG, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Germany
    Eur J Health Econ 15:577-89. 2014
  5. doi request reprint [Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data]
    J Ruof
    Hoffmann La Roche Ltd, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Deutschland
    Z Rheumatol 73:65-73. 2014
  6. ncbi request reprint Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients
    Jörg Ruof
    Roche Pharmaceuticals, Nutley, NJ 07110 USA
    Clin Drug Investig 27:469-79. 2007
  7. ncbi request reprint Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland
    J Ruof
    Health Services Research Unit, Division of Rheumatology, Center of Internal Medicine, Hannover Medical School, Hannover, Germany
    Int J Obes (Lond) 29:517-23. 2005
  8. ncbi request reprint [Conceptual and methodological basics of cost assessments in rheumatology]
    J Ruof
    Abteilung für Rheumatologie, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    Z Rheumatol 63:372-9. 2004
  9. ncbi request reprint Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards
    Jörg Ruof
    Division of Rheumatology, Hannover Medical School, 30625 Hannover, Germany
    Eur J Health Econ 5:64-9. 2004
  10. pmc Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources
    J Ruof
    Division of Rheumatology, Hannover Medical School, Hannover, Germany
    Ann Rheum Dis 62:544-9. 2003

Detail Information

Publications22

  1. ncbi request reprint Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required?
    Jörg Ruof
    Hannover Medical School, Hannover, Germany
    Arthritis Rheum 51:774-81. 2004
    ..To investigate the level of detail required in self-reported health care utilization questionnaires for administration to patients with rheumatoid arthritis (RA)...
  2. pmc Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
    Jörg Ruof
    Roche Pharma AG, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Germany
    Drugs R D 15:221-6. 2015
    ..Moreover, in order to fully acknowledge the benefit of a new medicinal product, mortality, morbidity and HRQoL should be weighted differentially, according to the condition. ..
  3. doi request reprint Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany
    Jörg Ruof
    Roche Pharma AG, Grenzach Wyhlen, Germany Medical School of Hanover, Hanover, Germany Electronic address
    Health Policy 118:242-54. 2014
    ..We aimed to compare endpoints and related benefit categories used in marketing authorisation to those considered by G-BA in the field of oncology...
  4. pmc Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
    Jörg Ruof
    Roche Pharma AG, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Germany
    Eur J Health Econ 15:577-89. 2014
    ..The aim of this investigation was to analyse the outcomes 18 months after introduction of the new legislation and to identify critical areas requiring further discussion and development...
  5. doi request reprint [Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data]
    J Ruof
    Hoffmann La Roche Ltd, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Deutschland
    Z Rheumatol 73:65-73. 2014
    ..Unlike RCT, NIS therefore have no actual inclusion and exclusion criteria, allowing the study of broad heterogeneous patient populations...
  6. ncbi request reprint Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients
    Jörg Ruof
    Roche Pharmaceuticals, Nutley, NJ 07110 USA
    Clin Drug Investig 27:469-79. 2007
    ....
  7. ncbi request reprint Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland
    J Ruof
    Health Services Research Unit, Division of Rheumatology, Center of Internal Medicine, Hannover Medical School, Hannover, Germany
    Int J Obes (Lond) 29:517-23. 2005
    ..The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes...
  8. ncbi request reprint [Conceptual and methodological basics of cost assessments in rheumatology]
    J Ruof
    Abteilung für Rheumatologie, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    Z Rheumatol 63:372-9. 2004
    ..In summary, no 'gold standard' has been established for costing studies yet. However, valid costing approaches might follow the flow scheme presented in this analysis...
  9. ncbi request reprint Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards
    Jörg Ruof
    Division of Rheumatology, Hannover Medical School, 30625 Hannover, Germany
    Eur J Health Econ 5:64-9. 2004
    ..However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research...
  10. pmc Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources
    J Ruof
    Division of Rheumatology, Hannover Medical School, Hannover, Germany
    Ann Rheum Dis 62:544-9. 2003
    ..To develop a systematic set of German cost data in rheumatoid arthritis (RA) based solely on valid healthcare payer's cost data sources...
  11. doi request reprint Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings
    Timm Kirchhoff
    Division of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany
    Rheumatology (Oxford) 50:756-61. 2011
    ..Comparison of overall RA-related costs and of relative contribution of single-cost domains before and after the introduction of TNF-blocking agents in Germany...
  12. ncbi request reprint Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'
    J L Hülsemann
    Division of Rheumatology, Hannover Medical School, Hannover, Germany
    Rheumatol Int 26:704-11. 2006
    ....
  13. ncbi request reprint Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis
    Sonja Merkesdal
    Hannover Medical School, Division of Rheumatology, Carl Neuberg Str 1, 30623 Hannover, Germany
    Expert Opin Pharmacother 5:1881-6. 2004
    ..Still, data on economic outcomes of RA trials are sparse and further cost-effectiveness and cost-utility evaluations are needed...
  14. doi request reprint Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches
    Sonja Merkesdal
    Division of Rheumatology, Hannover Medical School, Carl Neuberg Str 1, 30623 Hannover, Germany
    Expert Rev Pharmacoecon Outcomes Res 2:313-8. 2002
    ..These recommendations are proposed to give an orientation in a field of heterogeneous strategies in order to improve comparability of indirect cost assessment...
  15. pmc Direct costs related to rheumatoid arthritis: the patient perspective
    J L Hülsemann
    Division of Rheumatology, Hannover Medical School, Hannover, Hannover, Germany
    Ann Rheum Dis 64:1456-61. 2005
    ..To determine rheumatoid arthritis related out of pocket expenditure (OOPE) in Germany and to disaggregate the total OOPE into contributing cost domains...
  16. pmc Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
    Jörg Ruof
    Roche Pharma AG, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Germany
    Health Econ Rev 6:46. 2016
    ....
  17. ncbi request reprint Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis
    S Merkesdal
    Division of Rheumatology, Hannover Medical School, Center for Health Economics, University of Hannover, Germany
    J Rheumatol 28:657-61. 2001
    ..A preliminary scheme to categorize cost assessment in rheumatic conditions is presented. The adoption of standards for economic evaluation would greatly facilitate national and international comparisons...
  18. ncbi request reprint Diffusion of innovations: treatment of Alzheimer's disease in Germany
    Jörg Ruof
    Arbeitsbereich Versorgung und Okonomie, Abteilung Rheumatologie, Medizinische Hochschule Hannover, Carl Neuberg Str 5, D 30625 Hannover, Germany
    Health Policy 60:59-66. 2002
    ..This leads to a more short-term cost control strategy instead of long-term disease management and cost saving approaches...
  19. ncbi request reprint Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics
    J Ruof
    Division of Rheumatology, Hannover Medical School, , , Germany
    J Rheumatol 28:662-5. 2001
    ....
  20. pmc Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases
    Thomas Staab
    Roche Pharma AG, Emil Barrell Str 1, 79639, Grenzach Wyhlen, Germany
    BMC Health Serv Res 16:651. 2016
    ..In this study the acceptance of clinically acknowledged primary endpoints (PEPs) from regulatory trials in EBAs conducted by the G-BA was evaluated across three therapeutic areas...
  21. ncbi request reprint Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns
    J Ruof
    Health Services Research Unit, Department of Rheumatology, Hannover Medical School, Hannover, Germany
    Prev Med 35:48-53. 2002
    ..The objective of our study was to identify the type and prevalence of lipid-lowering medications in a German outpatient CHD population and to examine the impact of applied treatment regimens on serum lipid levels...
  22. ncbi request reprint Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease
    S Merkesdal
    Hannover Medical School, Germany
    Arthritis Rheum 44:528-34. 2001
    ....